ISAB: Sales declined but cost control improved results; FDA collaboration and new partnerships drive outlook

About this update from Inhalation Sciences Sweden Ab

Net sales and order backlog declined year-over-year, but cost reductions improved operating loss by 12%. Strategic partnerships, FDA collaboration, and new publications support future growth, though profitability and financing remain key risks.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Inhalation Sciences Sweden Ab